1. Home
  2. REGN vs DEO Comparison

REGN vs DEO Comparison

Compare REGN & DEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • DEO
  • Stock Information
  • Founded
  • REGN 1988
  • DEO 1886
  • Country
  • REGN United States
  • DEO United Kingdom
  • Employees
  • REGN N/A
  • DEO N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • DEO Beverages (Production/Distribution)
  • Sector
  • REGN Health Care
  • DEO Consumer Staples
  • Exchange
  • REGN Nasdaq
  • DEO Nasdaq
  • Market Cap
  • REGN 63.4B
  • DEO 61.6B
  • IPO Year
  • REGN 1991
  • DEO N/A
  • Fundamental
  • Price
  • REGN $490.28
  • DEO $108.92
  • Analyst Decision
  • REGN Buy
  • DEO Strong Buy
  • Analyst Count
  • REGN 23
  • DEO 2
  • Target Price
  • REGN $891.17
  • DEO N/A
  • AVG Volume (30 Days)
  • REGN 1.5M
  • DEO 732.0K
  • Earning Date
  • REGN 04-29-2025
  • DEO 07-12-2025
  • Dividend Yield
  • REGN 0.36%
  • DEO 3.80%
  • EPS Growth
  • REGN 16.49
  • DEO N/A
  • EPS
  • REGN 39.43
  • DEO 1.61
  • Revenue
  • REGN $14,085,700,000.00
  • DEO $20,208,000,000.00
  • Revenue This Year
  • REGN N/A
  • DEO $3.65
  • Revenue Next Year
  • REGN $6.97
  • DEO $2.88
  • P/E Ratio
  • REGN $12.43
  • DEO $16.80
  • Revenue Growth
  • REGN 7.52
  • DEO N/A
  • 52 Week Low
  • REGN $485.00
  • DEO $100.72
  • 52 Week High
  • REGN $1,211.20
  • DEO $142.73
  • Technical
  • Relative Strength Index (RSI)
  • REGN 32.32
  • DEO 41.91
  • Support Level
  • REGN $590.15
  • DEO $107.90
  • Resistance Level
  • REGN $608.17
  • DEO $110.49
  • Average True Range (ATR)
  • REGN 18.79
  • DEO 1.26
  • MACD
  • REGN -3.82
  • DEO -0.79
  • Stochastic Oscillator
  • REGN 3.98
  • DEO 13.51

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About DEO Diageo plc

Formed in 1997 through the merger of Grand Metropolitan and Guinness, Diageo is the largest distiller globally by sales. Diageo acquired some of the Seagram assets in 2001, which gave it brands such as Captain Morgan rum and Crown Royal Canadian whisky. Since then, mergers and acquisitions have mostly been bolt-on in nature, plugging gaps in the company's product and geographic portfolio. The firm has also shed noncore brands over the years, including the majority of its wine assets in 2015.

Share on Social Networks: